<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">INTERFERON BETA-1b</span><br/>(in-ter-fer'on)<br/><span class="topboxtradename">Betaseron<br/></span><b>Classifications:</b> <span class="classification">immunomodulator</span>; <span class="classification">interferon</span><br/><b>Prototype: </b>Interferon alfa-2a<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.3 mg vial</p>
<h1><a name="action">Actions</a></h1>
<p>Interferon beta-1b is a glycoprotein produced by recombinant DNA techniques using a strain of <i>E. coli.</i> Naturally occurring interferon beta-1b is produced principally by fibroblasts and macrophages.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Both natural and recombinant DNA interferon beta-1b possess antiviral, antiproliferative, antitumor, and immunomodulatory
         activity. The use of interferon beta-1b for multiple sclerosis (MS) is based on the assumption that MS is an immunologically
         mediated illness.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Relapsing and relapsing-remitting multiple sclerosis.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>AIDS, AIDS-related Kaposi's sarcoma, metastatic renal cell carcinoma, malignant melanoma, cutaneous T-cell lymphoma, acute
         hepatitis C.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Previous hypersensitivity to interferon beta-1b or human albumin, pregnancy (category C) but may cause a spontaneous abortion,
         lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Suicidal/mental disorders especially chronic depression; seizures; cardiac disease. Safety and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Multiple Sclerosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 0.25 mg (8 million IU) q.o.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Reconstitute by adding 1.2 mL of the supplied diluent (0.54% NaCl) to vial and gently swirl. Do <small>NOT</small> shake. The resultant solution contains 0.25 mg (8 million units)/mL.
         </li>
<li>Discard reconstituted solution if it contains particulate matter or is discolored. Also discard unused solution.</li>
<li>Rotate injection sites; use 27-gauge needle to administer drug.</li>
<li>Store vials under refrigeration, 2°8° C (36°46° F) or at room temperature.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, <span class="speceff-common">fever,</span> fatigue, dizziness, lethargy, depression, somnolence, weakness, agitation, malaise, confusion or reduced ability to concentrate,
      anxiety, dementia, emotional lability, depersonalization, suicide attempts. <span class="typehead">CV:</span> Tachycardia, peripheral edema, CHF (rare). <span class="typehead">GI:</span> Nausea, vomiting, <span class="speceff-common">diarrhea</span>. <span class="typehead">Hematologic:</span>
<span class="speceff-common">Leukopenia, thrombocytopenia,</span> anemia. <span class="typehead">Metabolic:</span> Hypocalcemia, elevated serum creatinine, elevated liver transaminases, autoimmune hepatitis, <span class="speceff-life">hepatic failure</span>. <span class="typehead">Skin:</span> Local skin necrosis at injection site, rash, <span class="speceff-common">pain at injection site</span>. <span class="typehead">Body as a Whole:</span> Alopecia, myalgias, <span class="speceff-common">flu-like syndrome</span>. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Zidovudine (AZT)</b> levels are increased, resulting in toxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> About 50% absorbed from SC sites. <span class="typehead">Distribution:</span> Penetrates intact bloodbrain barrier poorly; crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Rapidly inactivated in body fluids and tissue. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor vital signs, neurologic status, and neuropsychiatric status frequently during therapy.</li>
<li>Lab tests: Monitor liver function at 1, 3, and 6 mo after initiation of therapy and as clinically warranted thereafter; monitor
            renal function, complete blood counts, and serum electrolytes periodically.
         </li>
<li>Assess for and promptly treat flu-like symptom complex (fever, chills, myalgia, etc.).</li>
<li>Assess injection sites; pain and redness are common reactions. Report tissue ulceration promptly.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn and understand potential adverse drug reactions.</li>
<li>Learn proper technique for solution preparation and injection.</li>
<li>Self-medicate with acetaminophen (if not contraindicated) if flu-like symptom complex develops.</li>
<li>Avoid prolonged exposure to sunlight.</li>
<li>Use caution when performing hazardous activities until response to drug is known.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>